Article Text

Download PDFPDF

1244 Polarized immune responses reveal actionable therapeutic targets in cutaneous adverse events to checkpoint inhibitors
  1. Stephanie Gu1,
  2. Elena Goleva2,
  3. Andrea P Moy3,
  4. Kwami Ketosugbo3,
  5. Lukas Kraehenbuehl4,
  6. Tara Maier3,
  7. Trina Salvador3,
  8. Neil J Shah5,
  9. Ryan Weight6,
  10. Veronica Rotemberg3,
  11. Jeffrey A Kern2,
  12. Donald Y Leung2 and
  13. Mario E Lacouture3
  1. 1New York, NY, USA
  2. 2National Jewish Health, Denver, CO, USA
  3. 3Memorial Sloan Kettering Cancer Center, New York, NY, USA
  4. 4Weill Cornell Medicine, New York, NY, USA
  5. 5Memorial Sloan Kettering Cancer Center, Washington, DC, USA
  6. 6The Skin Cancer Institute, Denver, CO, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Immune-related cutaneous adverse events (ircAE) occur frequently and present with various phenotypes, suggesting distinct immunologic pathways underlying their development. Currently, ircAE treatment is empiric. Comprehensive immunologic endotype profiling is needed to understand the mechanisms driving the development of ircAEs and provide a rational basis for treatment with therapies that target specific endotypes.

Methods Patients on CPIs were recruited from Memorial Sloan Kettering Cancer Center (MSK) (New York, New York), National Jewish Health (Denver, Colorado), and The Melanoma and Skin Cancer Institute (Denver, Colorado) from 9/2020 to 12/2022. Patients with ircAEs ≥ grade 2 were enrolled into cohort 1 and patients without ircAE were enrolled into cohort 2 (controls). At the initial visit, patients in both cohorts underwent detailed phenotyping, biospecimen collection, and patient-reported outcome (PRO) questionnaires.

Results Demographics of enrolled patients are depicted in (table 1). Clinical evaluation yielded 8 distinct ircAE phenotypes (figure 1). Patients with all ircAE phenotypes except vitiligo reported reduced quality of life (p<0.01). Complete blood counts (CBC) of patients with ircAEs did not differ from those of control patients, except for decreased lymphocytes in pruritus and lichenoid ircAEs (p<0.05). Patients with pruritus had significant elevations (all values shown as median log10 fold change compared to controls) in IL-4 (0.41) and IL - 12p70 (0.22) in the skin and IL-4 (0.31), IL-5 (0.16), and IL-17A (0.19) in the plasma. Those with maculopapular ircAEs had elevations of all measured Th1, Th2, Th17/22, and regulatory cytokines in the skin (p<0.05-p<0.001) and IP-10, IL-4, IL-17a, and IL-10 (p<0.05-p<0.001) in the plasma. Psoriasiform, lichenoid, bullous pemphigoid, and vitiligo-like ircAEs were associated with significant upregulation of IP-10 (1.61, 1.06, 0.67, 0.66, respectively) in the skin. Finally, eczema and urticaria ircAEs had increased levels of IL-5 (0.32, 0.49, respectively) and IL-31 in the plasma (0.16, 0.31, respectively), with eczema also demonstrating a significant increase in the production of IP-10 (0.86). Compared to controls, histopathologic analysis of biopsies from lesional skin of all clinical phenotypes showed an increased density of lymphocytes (p<0.0001) and eosinophils (p<0.05-p<0.0001) ; increased neutrophilic infiltrate was also detected in psoriasiform (p<0.0001) and urticarial ircAEs (p<0.001).

Conclusions A distinct endotype has been identified for clinical phenotypes of ircAEs. This identification of upregulated immune pathways will allow individualized management through rational selection of targeted treatments. These endotypes are not detected with CBCs, suggesting that expanded cytokine analysis of skin and plasma is needed to understand mechanisms of ircAE development and guide therapy.

Ethics Approval All subjects gave their informed consent for inclusion before they participated in the study. The study was approved by the institutional review board at all respective participating institutions.

Abstract 1244 Table 1

Patient Demographics

Abstract 1244 Figure 1

ircAE phenotypes (n=139)

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.